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Abstract (word count: 344):
Acetylcholine (ACh) is a neurotransmitter known to modulate cognitive functions, including learning and
memory. Many cholinergic drugs bind to highly conserved orthosteric binding sites of muscarinic
receptors (mAChRs) and are therefore likely to activate all mAChR subtypes (M1-M5) to some degree,
including M3, which is primarily thought to mediate most of the adverse peripheral side effects associated
with cholinergic agonists. Drugs that bind to allosteric sites, however, have shown promise for targeting
specific muscarinic receptor subtypes. There are two broad classes of allosteric activators: allosteric
agonists, which can act to enhance memory in the absence of ACh, and positive allosteric modulators
(PAMs), which enhance the ability of ACh to activate mAChRs and thus depend on ACh to produce a
similar effect. In the present study, we sought to identify the contribution of M1 and M4 receptor subtypes
to hippocampal memory, since these receptors are profusely found in memory related structures such as
the hippocampus and believed to be crucial for memory. We therefore hypothesized that selective M1 or
M4 activators would act to enhance memory in an object recognition task. To this end we utilized low,
medium and high doses of the novel M1 allosteric agonist, VU0364572, M1 PAM, BQCA, or the novel M4
PAM, VU0152100. Importantly, experimenters were blind to drug condition and drug order was
randomized for subcutaneous injection to rats 30 minutes before they performed an object recognition
memory task. Interestingly, the results suggested that the efficacy of the drugs might depend on a rat's
baseline level of memory performance. In particular, when drug effects in low baseline performers
(discrimination indices < 0.60) and high baseline performers (discrimination indices > 0.60) were
analyzed separately, simple comparisons indicated that a low dose of VU0152100 increased memory
performance in rats with low baseline performance. To our knowledge, this is the first demonstration that
potentiating the M4 mAChR subtype can increase memory performance. Fully understanding the
behavioral effects of activating mAChR subtypes in the brain will be essential for developing drugs for
memory deficits associated with disorders such as Alzheimer’s disease and schizophrenia.

